Should we start and continue growth hormone (GH) replacement therapy in adult; with GH deficiency?

References

• Salomon F, Cuneo R D, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults. N Engl J Med 1989; 321: 1797–803
   PubMed Web of Science ®Google Scholar
• Jorgensen J OL, Pedersen S A, Thuesen L, Jorgensen J, Ingemann-Hansen T, Skakkebaek N E. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989; i: 1221–5
   Google Scholar
• De Boer H, Biok G J, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev 1995; 16: 63–86
   PubMed Web of Science ®Google Scholar
• Invited Report of a Workshop. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 379–81
   Google Scholar
• Nicolson A, Toogood A A, Rahim A, Shalet SM. The prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. Clin Endocrinol 1996; 44: 311–6
   PubMed Web of Science ®Google Scholar
• Juul A, Kastrup K W, Pedersen S A, Skakkebaek NE. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. J Clin Endocrinol Metab 1997; 82: 1195–201
   PubMed Web of Science ®Google Scholar
• Maghnie M, Strigazzi C, Tinelli C, Autelli M, Cisternino M, Loche S. Growth hormone (GH) deficiency (GHD) of childhood onsef: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab 1999; 84: 1324–8
   Google Scholar
• Bengtsson B A, Johannsson G, Shalet S M, Simpson H, Sonksen P. Therapeutic controversy. Treatment of growth hormone deficiency in adults. J Clin Endocrinol Metab 2000; 85: 933–42
   PubMed Web of Science ®Google Scholar
• Carroll P V, Christ E R, Bengtsson B A, Carlsson L, Christiansen J S, Clemmons D. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998; 83: 382–95
   PubMed Web of Science ®Google Scholar
• Attanasio A F, Lamberts S WJ, Matranga A MC, Birkett M A, Bates P C, Valk N K. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997; 82: 82–8
   PubMed Web of Science ®Google Scholar
• Bengtsson B A, Abs R, Bennmarker H, Monson J P, Feldt-Rasmussen U, Hernberg-Ståhl. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 3929–35
   PubMed Web of Science ®Google Scholar
• Johannsson G, Bjarnason R, Bramnert M, Carlsson L MS, Degerblad M, Manhem P. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age and gender. J Clin Endocrinol Metab 1996; 81: 1575–81
   PubMed Web of Science ®Google Scholar
• Janssen Y JH, Doornbos J, Roelfsema F. Changes in muscle volume, strength, and bioenergetics during recombinant human growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 279–84
   PubMed Web of Science ®Google Scholar
• Holmes S J, Economou G, Whitehouse R J, Adams J E, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 1994; 78: 669–74
   PubMed Web of Science ®Google Scholar
• Toogood A A, Adam J E, O'Neill P, Shalet SM. Elderly patients with adult-onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 1997; 82: 1462–6
   PubMed Web of Science ®Google Scholar
• Merola B, Cittadini A, Colao A, Longobardi S, Fazio S, Sabatini D. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993; 77: 1658–61
   PubMed Web of Science ®Google Scholar
• Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D. Bodycomposition, hone metabolism, heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671–6
   PubMed Web of Science ®Google Scholar
• Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I. Cardiac performance and mass in adults with hypo-pituitarism: effects of one year of growth hormone treatment. J Clin Endocrinol Metab 1995; 80: 659–66
   PubMed Web of Science ®Google Scholar
• Johansson J O, Fowelin J, Landin K, Lager I, Bengtsson BA. Growth hormone-deficient adults are insulin-resistant. Metabolism 1995; 44: 1126–9
   PubMed Web of Science ®Google Scholar
• Hew F L, Koschmann M, Christopher M, Rantzau C, Vaag A, Ward G. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab 1996; 81: 555–64
   PubMed Web of Science ®Google Scholar
• Cuneo R C, Salomon F, Wiles M, Hesp R, Sonksen PH. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991; 70: 688–94
   PubMed Web of Science ®Google Scholar
• Whitehead H M, Boreham C, McIlrath E M, Sheridan B, Kennedy L, Atkinson A B. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clin Endocrinol 1992; 36: 45–52
   PubMed Web of Science ®Google Scholar
• Bengtsson B A, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993; 76: 309–17
   PubMed Web of Science ®Google Scholar
• Ter Maaten J C, De Boer H, Kamp O, Stuurman L, Van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999; 84: 2373–80
   PubMed Web of Science ®Google Scholar
• Baum H BA, Biller B MK, Finkelstein J S, Cannistraro K B, Oppenheim D S, Schoenfeld D A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized placebo-controlled trial. Ann Intern Med 1996; 125: 883–90
   PubMed Web of Science ®Google Scholar
• Jorgensen J OL, Thuesen L, Miiller J, Ovesen P, Skakkebaek, Christiansen JS. Three years of growth hormone treatment in growth-hormone deficient adults: near normalization of body composition and physical performance. Eur J Endocrinol 1994; 130: 224–8
   PubMed Web of Science ®Google Scholar
• Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol 1993; 39: 409–15
   PubMedGoogle Scholar
• Inzucchi S E, Robbins RJ. Growth hormone and the maintenance of adult bone density. Clin Endocrinol 1996; 45: 665–73
   Google Scholar
• Bravenboer N, Holzmann P, De Boer H, Roos J C, Van der Veen E A, Lips P. The effect of growth hormone on histomorphometric indices of bone structure and bone turnover in growth hormone deficient men. J Clin Endocrinol Metab 1997; 82: 1818–22
   Google Scholar
• Johannsson G, Rosén T, Bosaeus I, Sjostrom L, Bengtsson BA. TWO years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Encocrinol Metab 1996; 81: 2865–73
   PubMed Web of Science ®Google Scholar
• Rahim A, Holmes S J, Adams J E, Shalet SM. Long-term change in the bone mineral density of adults with adult onset growth hormone (GH) deficiency in response to short or long-term GH replacement therapy. Clin Endocrinol 1998; 48: 463–9
   PubMedGoogle Scholar
• Colao A, Di Somna C, Pivonello R, Loche S, Aimaretti G, Cerbone G. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab 1999; 84: 1919–24
   PubMed Web of Science ®Google Scholar
• Rostn T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997; 137: 240–5
   Google Scholar
• Johannsson G, Grimby G, Sunnerhagen K S, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab 1997; 82: 2877–84
   PubMedGoogle Scholar
• Wallymahed M E, Foy P, Shaw D, Hutcheon R, Edwards R HT, MacFarlane IA. Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol 1997; 47: 439–46
   Google Scholar
• Jorgensen J OL, Vahl N, Hansen T B, Thuesen L, Hagen C, Christiansen JS. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clin Endocrinol 1996; 45: 681–8
   PubMed Web of Science ®Google Scholar
• Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr Rev 1994; 15: 555–73
   PubMed Web of Science ®Google Scholar
• Cuneo R C, Salomon F, Wilmshurst P, Byrne C, Wiles C M, Hesp R. Cardiovascular effects of growth hormone treatment in growth-hormone deficient adults: stimulation of the renin-aldosterone system. Clin Sci 1991; 81: 587–92
   PubMed Web of Science ®Google Scholar
• Caidahl K, Eden S, Bengtsson BA. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994; 40: 393–400
   PubMedGoogle Scholar
• Nass R, Huber R M, Klauss V, Miiller O A, Schopohl J, Strasburger CJ. Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood. J Clin Endocrinol Metab 1995; 80: 552–7
   PubMed Web of Science ®Google Scholar
• Beshyah S A, Shahi M, Foale R, Johnston DG. Cardiovascular effects of prolonged growth hormone replacement in adults. J Intern Med 1995; 237: 35–42
   Google Scholar
• Thuesen L, Jorgensen J OL, Miiller J R, Kristensen Bø, Skakkebaek N E, Vahl N. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol 1994; 41: 615–20
   PubMed Web of Science ®Google Scholar
• Johannsson G, Bengtsson B A, Anderson B, Isgaard J, Caidahl K. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults. Preliminary data in a small group of patients. Clin Endocrinol 1996; 45: 305–14
   Google Scholar
• Johannsson G, Mlrin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 1997; 82: 7272–734
   Google Scholar
• Hwu C M, Kwok C F, Lai T Y, Shih K C, Lee T S, Hsiao L C. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997; 82: 3285–92
   Google Scholar
• Press M. Growth hormone and metabolism. Diabetes Metab Rev 1988; 4: 391–414
   PubMedGoogle Scholar
• Fowelin J, Attvall S, Lager I, Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 1993; 42: 1443–7
   PubMed Web of Science ®Google Scholar
• O'Neal D N, Kalfas A, Dunning P L, Christopher M J, Sawyer S D, Ward G M. The effects of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis. J Clin Endocrinol Metab 1994; 79: 975–83
   PubMed Web of Science ®Google Scholar
• Weaver J U, Monson J P, Noonan K, John W G, Edwards A, Evans A. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypo-pituitary adults. J Clin Endocrinol Metab 1995; 80: 153–9
   PubMedGoogle Scholar
• Beshyah S A, Henderson A, Niththyananthan R, Skinner E, Anyaoku V, Richmond W. The effects of short and long term growth hormone replacement therapy in hypo-pituitary adults on lipid and carbohydrate tolerance. J Clin Endocrinol Metab 1995; 80: 356–63
   PubMed Web of Science ®Google Scholar
• Merimee T J, Felig P, Marliss E, Fineberg S E, Cahill GG. Glucose and lipid homeostasis in the absence of human growth hormone. J Clin Invest 1971; 50: 574–82
   Google Scholar
• Al-Shoumer K A, Gray R, Anyaoku V, Hughes C, Beshyah S, Richmond W. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol 1998; 48: 795–802
   PubMed Web of Science ®Google Scholar
• Garry P, Collins P, Devlin JG. An open 36-month study of lipid changes with growth hormone in adults: lipid changes following replacement of growth hormone in adult acquired growth hormone deficiency. Eur J Endocrinol 1996; 134: 61–6
   Google Scholar
• Johansson J O, Landin K, Johansson G, Tengborn L, Bengtsson BÅ. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-I and tissue plasminogen activator in growth hormone-deficient adults. Thromb Haemost 1996; 76: 422–8
   PubMed Web of Science ®Google Scholar
• Evans L M, Davies J S, Anderson R A, Ellis G R, Jackson S K, Lewis M J. The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. Eur J Endocrinol 2000; 142: 254–62
   Google Scholar
• Rosén T, Bengtsson BÅ. Premature mortality due to cardiovascular disease hypopituitarism. Lancet 1990; 336: 285–8
   PubMed Web of Science ®Google Scholar
• Bates A S, Van't Hoff W, Jones P J, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996; 81: 1169–72
   PubMed Web of Science ®Google Scholar
• Wiren L, Bengtsson B A, Johannsson G. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin Endocrinol 1998; 48: 613–20
   PubMedGoogle Scholar
• Deijen J B, De Boer H, Van der Veen EA. Cognitive changes during growth hormone replacement in adult men. Psychoneuroendocrinology 1998; 23: 45–55
   PubMed Web of Science ®Google Scholar
• Murray R D, Skillcorn C J, Howell S J, Lissett C A, Rahim A, Shalet SM. Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clin Endocrinol 1999; 50: 749–57
   PubMed Web of Science ®Google Scholar
• Woodhouse L, Asa S L, Scott G, Thomas S G, Ezzat S. Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adiults. J Clin Endocrinol Metab 1999; 84: 4570–7
   Google Scholar
• Burman P, Johansson A G, Siegbahn A, Vessby B, Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82: 550–5
   PubMed Web of Science ®Google Scholar
• Johansson A G, Engstrom B E, Ljunghall S, Karlsson F A, Burman P. Gender differences in the effects of long term growth (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 2002–7
   PubMed Web of Science ®Google Scholar
• Verhelst J, Abs R, Vandeweghe M, Mockel J, Legros J J, Copinschi G. Two years of replacement therapy in adults with growth hormone deficiency. Clin Endocrinol 1997; 47: 485–94
   PubMed Web of Science ®Google Scholar
• Holmes S J, Shalet SM. Characteristics of adults who wish to enter a trial of growth hormone replacement. Clin Endocrinol 1995; 42: 613–8
   Google Scholar
• De Boer H, Van der Veen EA. Guidelines for optimizing growth hormone replacement therapy in adults. Horm Res 1997; 48: 21–30, (Suppl 5)
   PubMedGoogle Scholar
• Wright A D, Hill D M, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med 1970; 39: 1–16
   PubMedGoogle Scholar
• Alexander L, Appleton D, Hall R, Ross W M, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 1980; 12: 71–79
   PubMed Web of Science ®Google Scholar
• Abs R, Bengtsson B A, Hernberg-Stlhl E, Monson J P, Tauber J P, Wilton P. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 1999; 50: 703–13
   PubMed Web of Science ®Google Scholar
• Gomez J M, Gomez N, Fiter J, Soler J. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement. Horm Metab Res 2000; 32: 66–70
   PubMedGoogle Scholar
• Biller B M, Sesmilo G, Baum H B, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab 2000; 85: 970–6
   PubMed Web of Science ®Google Scholar
• Johannsson G, Albertsson-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. J Clin Endocrinol Metab 1999; 84: 4516–24
   Google Scholar
• Bucher H C, Griffith L E, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187–95
   PubMed Web of Science ®Google Scholar
• Reid IR. Pharmacologic management of osteoporosis in postmenopausal women: a comparative review. Drugs Aging 1999; 15: 349–63
   PubMed Web of Science ®Google Scholar
• Bone H G, Greenspan S L, McKeever C, Bell N, Davidson M, Downs R W. Alendronate and estrogen effects in postmeopausal women with low bone mineral density. Alendronate/estrogen study group. J Clin Endocrinol Metab 2000; 85: 727–33
   Google Scholar
• Janssen Y JH, Frolich M, Roelfsema F. A low starting dose of genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 1997; 89: 129–35
   Google Scholar
• Johannsson G, Rosin T, Bengtsson BA. Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol 1997; 47: 571–81
   PubMed Web of Science ®Google Scholar
• Hindmarsh P C, Brook CG. Compliance with growth hormone treatment — is it a problem. Horm Res 1999; 51: 104–8, Suppl 3
   PubMedGoogle Scholar